<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-32876" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Daptomycin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Shivali</given-names>
          </name>
          <aff>Massachusetts General Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saw</surname>
            <given-names>Stephen</given-names>
          </name>
          <aff>Hospital of the UPenn</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivali Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Saw declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-32876.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Daptomycin is a cyclic lipopeptide antibiotic derived from the organism <italic toggle="yes">Streptomyces roseosporus</italic>&#x000a0;used to treat various bacterial infections caused by gram-positive bacteria, including methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) and vancomycin-resistant enterococci (VRE). Daptomycin is administered for&#x000a0;various FDA-approved and off-label clinical uses. This educational activity for healthcare professionals reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of daptomycin, providing critical knowledge for interprofessional team members treating conditions where daptomycin is appropriate.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of daptomycin.</p></list-item><list-item><p>Assess&#x000a0;the FDA-approved and off-label&#x000a0;uses of daptomycin.</p></list-item><list-item><p>Evaluate&#x000a0;the adverse reactions associated with daptomycin therapy.</p></list-item><list-item><p>Implement effective collaboration among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from daptomycin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32876">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-32876.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Daptomycin is a cyclic lipopeptide antibiotic derived from the organism <italic toggle="yes">Streptomyces </italic><italic toggle="yes">roseosporus</italic>. Daptomycin treats various bacterial infections caused by gram-positive bacteria, including methicillin-resistant <italic toggle="yes">Staphylococcus aureus</italic>&#x000a0;and vancomycin-resistant enterococci (VRE). Daptomycin&#x000a0;is prescribed for various&#x000a0;FDA-approved and off-label clinical uses.<xref ref-type="bibr" rid="article-32876.r1">[1]</xref><xref ref-type="bibr" rid="article-32876.r2">[2]</xref><xref ref-type="bibr" rid="article-32876.r3">[3]</xref><xref ref-type="bibr" rid="article-32876.r4">[4]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients&#x000a0;<xref ref-type="bibr" rid="article-32876.r5">[5]</xref><xref ref-type="bibr" rid="article-32876.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">S aureus&#x000a0;</italic>bacteremia in adult patients, including those with right-sided infective endocarditis&#x000a0;<xref ref-type="bibr" rid="article-32876.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">S aureus</italic> bacteremia in pediatric patients&#x000a0;<xref ref-type="bibr" rid="article-32876.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic foot infections&#x000a0;<xref ref-type="bibr" rid="article-32876.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Cerebrospinal fluid shunt infections&#x000a0;<xref ref-type="bibr" rid="article-32876.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Osteomyelitis or septic arthritis due to&#x000a0;MRSA<italic toggle="yes">&#x000a0;</italic><xref ref-type="bibr" rid="article-32876.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Native vertebral osteomyelitis&#x000a0;<xref ref-type="bibr" rid="article-32876.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Intracranial or&#x000a0;spinal epidural abscess&#x000a0;<xref ref-type="bibr" rid="article-32876.r13">[13]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Prosthetic joint infection caused by <italic toggle="yes">Staphylococcus</italic>&#x000a0;or <italic toggle="yes">Enterococcus</italic>&#x000a0;spp<italic toggle="yes">&#x000a0;</italic><xref ref-type="bibr" rid="article-32876.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Vancomycin-resistant enterococci (VRE) infections&#x000a0;<xref ref-type="bibr" rid="article-32876.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Daptomycin lock therapy in catheter-related bloodstream infections (CRBSI)&#x000a0;<xref ref-type="bibr" rid="article-32876.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>As monotherapy or in combination with linezolid for healthcare-associated meningitis or ventriculitis caused by <italic toggle="yes">Staphylococcus</italic>&#x000a0;spp when &#x003b2;-lactam agents or vancomycin are&#x000a0;ineffective or unsuitable (Infectious Disease Society of America)&#x000a0;<xref ref-type="bibr" rid="article-32876.r17">[17]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-32876.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Daptomycin is a cyclic lipopeptide antibiotic that exerts its bactericidal effect by disrupting multiple aspects of bacterial cell membrane function. Daptomycin binds to the cell membrane of susceptible organisms and causes a rapid depolarization of membrane potential. The loss of membrane potential leads to the intracellular inhibition of DNA, RNA, and protein synthesis, ultimately resulting in bacterial cell death. Daptomycin is only&#x000a0;effective against gram-positive bacteria.<xref ref-type="bibr" rid="article-32876.r18">[18]</xref><xref ref-type="bibr" rid="article-32876.r19">[19]</xref>&#x000a0;Evidence also suggests that daptomycin binds to bilayers containing cell wall lipid intermediates and forms a tripartite complex with lipid II and phosphatidylglycerol (PG). Calcium-bound daptomycin then oligomerizes and localizes at the division septum. This complex inhibits cell wall synthesis and disrupts the cell wall biosynthetic machinery. Prolonged exposure leads to the distribution of daptomycin throughout the cytoplasmic membrane, resulting in pore formation, membrane disruption, ion leakage, and, ultimately, cell death.<xref ref-type="bibr" rid="article-32876.r20">[20]</xref></p>
        <p><bold>Mechanism of resistance:&#x000a0;</bold>Daptomycin-resistant phenotypes are often associated with alterations in bacterial membrane composition and cell wall biosynthesis. A prevalent resistance mechanism involves changes in cell surface charge that repel daptomycin or modifications in the bacterial phospholipid phosphatidylglycerol.<xref ref-type="bibr" rid="article-32876.r21">[21]</xref></p>
        <p>
<bold>Pharmacokinetics/Pharmacodynamics</bold>
</p>
        <p>Daptomycin is a bactericidal antibiotic administered intravenously (IV).&#x000a0;The area under the concentration-time curve to minimum inhibitory concentration ratio (AUC/MIC) correlates well with the antimicrobial activity. The other pharmacological parameters are given below.</p>
        <p><bold>Absorption:</bold> IV daptomycin has a rapid onset of action. The steady-state trough concentrations are attained by the third day.</p>
        <p><bold>Distribution:</bold> The volume of distribution at steady-state (approximately 1.0 L/kg) in healthy adult patients is significant. The volume of distribution at steady-state in pediatric and critically ill patients is significantly lower. Protein binding ranges from 90% to 93% in the general population and decreases to 84% to 88% in patients with a creatinine clearance of less than 30 mL/min.</p>
        <p><bold>Metabolism:</bold> Research studies have indicated daptomycin is broken down into minimal amounts of oxidative metabolites. In vitro studies suggest&#x000a0;human liver microsomes do not metabolize daptomycin.<xref ref-type="bibr" rid="article-32876.r22">[22]</xref></p>
        <p><bold>Excretion:</bold>&#x000a0;Daptomycin is primarily eliminated as an unchanged drug in the urine (78%), with a lesser amount eliminated in feces (5.7%). Clearance is 8.3 to 9 mL/min/kg in adults with normal renal function. Pediatric patients have demonstrated increased clearance. The half-life of daptomycin is 8 to 9 hours in healthy adults with normal renal function. The elimination half-life can be significantly prolonged in patients with renal impairment (up to 28 hours). Pediatric patients&#x000a0;demonstrate a shorter elimination half-life.</p>
      </sec>
      <sec id="article-32876.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Daptomycin is available as 350 mg lyophilized powder for injection or reconstitution in a 50 mg/mL single-dose vial.&#x000a0;Different indications require different doses. The&#x000a0;recommended dose should be administered over 30 minutes in adults and children&#x000a0;older than 7. Daptomycin should be infused over 60 minutes in children aged 1 to 6. Daptomycin administration&#x000a0;may be pushed intravenously over 2 minutes in adult patients only.<xref ref-type="bibr" rid="article-32876.r23">[23]</xref><xref ref-type="bibr" rid="article-32876.r24">[24]</xref><xref ref-type="bibr" rid="article-32876.r25">[25]</xref>&#x000a0;To prevent excessive foaming and ensure appropriate reconstitution, the vial should not be shaken during or after reconstitution. The reconstituted solution remains stable for 12 hours at room temperature or 48 hours&#x000a0;if refrigerated.<xref ref-type="bibr" rid="article-32876.r26">[26]</xref></p>
        <p>
<bold>Adult and Pediatric Dosage</bold>
</p>
        <table-wrap id="article-32876.table0" position="float" orientation="portrait">
          <table style="width: 800px; float: left;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr>
                <td style="width: 144.875px; text-align: center;" rowspan="1" colspan="1">
<p>Indication</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Patients Group</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>Dosage and Dosing</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>Patients with Renal Impairment</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p>cSSSI</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Adults</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 4 mg/kg in 0.9% sodium chloride; injection over 2 minutes or infusion over 30 minutes; every 24 hours for 7 to 14 days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>CrCl 30 to 130 mL/min: No dosage adjustment is necessary</p>
<p>CrCl &#x0003c;30 mL/min: Patients are administered the standard dose every 48 hours&#x000a0;and monitored closely</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p>cSSSI</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 1 to 2 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 10 mg/kg; infused over 60 minutes; every 24 hours for up to 14 days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p>cSSSI</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 2 to 6 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 9 mg/kg; infused over 60 minutes; every 24 hours for up to 14 days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p>cSSSI</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 7 to 11 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 7 mg/kg; infused over 30 minutes; every 24 hours for up to 14 days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p>cSSSI</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 12 to 17 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 5 mg/kg; infused over 30 minutes; every 24 hours for up to 14 days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p><italic toggle="yes">S aureus&#x000a0;</italic>bacteremia, including&#x000a0;patients with right-sided infective endocarditis&#x000a0;</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Adults</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 6 mg/kg in 0.9% sodium chloride; injection over 2 minutes or infusion over 30 minutes; every 24 hours for&#x000a0;2 to&#x000a0;6 weeks. Limited safety data is available for&#x000a0;dosing longer than 28 days.</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>CrCl 30 to 130 mL/min: No dosage adjustment is necessary</p>
<p>CrCl &#x0003c;30 mL/min: Patients are administered the standard dose every 48 hours&#x000a0;and monitored closely</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p><italic toggle="yes">S aureus&#x000a0;</italic>bacteremia</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 1 to 6 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 12 mg/kg; infused over 60 minutes; every 24 hours for up to&#x000a0;42 days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p><italic toggle="yes">S aureus&#x000a0;</italic>bacteremia</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 7 to 11 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 9 mg/kg; infused over 30 minutes; every 24 hours for up to&#x000a0;42&#x000a0;days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
              <tr>
                <td style="width: 144.875px;" rowspan="1" colspan="1">
<p><italic toggle="yes">S aureus&#x000a0;</italic>bacteremia</p>
</td>
                <td style="width: 205.125px;" rowspan="1" colspan="1">
<p>Children (age 12 to 17 years)</p>
</td>
                <td style="width: 358px;" rowspan="1" colspan="1">
<p>IV 7 mg/kg; infused over 30 minutes; every 24 hours for up to&#x000a0;42&#x000a0;days</p>
</td>
                <td style="width: 457px;" rowspan="1" colspan="1">
<p>According to the manufacturer, daptomycin administration by injection is not indicated in pediatric patients with renal impairment because the dosage has not been established.</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>Daptomycin pharmacokinetics are not altered in moderate hepatic impairment, and no dosage adjustment is necessary for mild to moderate hepatic impairment. The pharmacokinetics of daptomycin in severe hepatic impairment (Child-Pugh Class C) have not been evaluated.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>Reduced renal function can lead to the accumulation of daptomycin, increasing the risk of adverse effects. Frequency adjustments are necessary for patients with a creatinine clearance of less than 30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). These patients should receive daptomycin every 48 hours compared to every 24 hours for patients with a CrCl &#x0003e;30 mL/min. Renal function and creatinine phosphokinase (CPK) levels should be monitored weekly in patients with renal impairment.<xref ref-type="bibr" rid="article-32876.r27">[27]</xref></p>
        <p><bold>Pregnancy considerations: </bold>Daptomycin is&#x000a0;a pregnancy category B drug; limited information is available on its use during pregnancy. Case reports have described the successful use of daptomycin during the second and third trimesters of pregnancy. Additionally, animal reproductive studies have not yet determined any evidence of fetal harm from maternal use of daptomycin. Nevertheless, a risk-benefit analysis should be conducted before initiating daptomycin in patients who are pregnant.</p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Low concentrations of daptomycin have been detected in breast milk (0.1% of the maternal dose). There is limited information on daptomycin's effects on breastfed infants or milk production. Like other antibiotics, maternal use of daptomycin may cause a non-dose-related change in neonatal bowel flora. Therefore, breastfed infants should be monitored for gastrointestinal disturbances. Breastfeeding mothers receiving treatment with daptomycin should be advised to consult with their provider and conduct a risk-benefit analysis before breastfeeding.<xref ref-type="bibr" rid="article-32876.r28">[28]</xref></p>
        <p><bold>Pediatric patients: </bold>The table provides the recommended dosage of daptomycin for pediatric patients. As mentioned above, daptomycin is not recommended for children younger than 12 months.<xref ref-type="bibr" rid="article-32876.r29">[29]</xref>&#x000a0;According to the Pediatric Infectious Diseases Society (PIDS) and Infectious Diseases Society of America (IDSA) 2021 guidelines for acute hematogenous osteomyelitis (AHO), if clindamycin resistance is 10% to 20% and MRSA resistance is 10% to 20%, patients who are moderate to severely ill should be treated with vancomycin/daptomycin/linezolid/ceftaroline.<xref ref-type="bibr" rid="article-32876.r30">[30]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>Older&#x000a0;adults are at an increased risk of daptomycin toxicity due to age-related changes in renal function or factors that may enhance exposure to the medication. However, no dosage adjustments are recommended for&#x000a0;patients with a creatinine clearance &#x0003e;30 mL/min.</p>
      </sec>
      <sec id="article-32876.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of daptomycin therapy include myopathy, rhabdomyolysis, eosinophilic pneumonia, and anaphylactic hypersensitivity reactions.&#x000a0;Patients may also&#x000a0;experience less severe adverse&#x000a0;reactions such as constipation, headache, insomnia, and skin rash.<xref ref-type="bibr" rid="article-32876.r31">[31]</xref>&#x000a0;There have been cases reported in patients with and without acute kidney injury. Therefore, weekly monitoring of creatine phosphokinase (CPK) levels is recommended for patients receiving daptomycin therapy. More frequent monitoring is recommended in patients with renal impairment or those receiving concomitant HMG-CoA reductase inhibitors (statins). Clinicians should discontinue treatment in patients with signs and symptoms of myopathy&#x000a0;and an elevated CPK (&#x0003e;5x upper normal limit (ULN) or &#x0003e;1000 units/L) and asymptomatic patients with a CPK elevation &#x0003e;10x ULN (or &#x0003e;2000 units/L). The incidence of myopathy increases with the administration of doses greater than recommended. Additionally, providers should consider temporarily discontinuing other agents associated with rhabdomyolysis (eg, statins) during daptomycin therapy.<xref ref-type="bibr" rid="article-32876.r32">[32]</xref><xref ref-type="bibr" rid="article-32876.r33">[33]</xref></p>
        <p>Daptomycin therapy is also associated with the development of eosinophilic pneumonia, which generally occurs 2 to 4 weeks after initiation. Patients require monitoring for signs and symptoms of eosinophilic pneumonia, including&#x000a0;new-onset or worsening fever and new infiltrate on chest imaging. Daptomycin therapy should be immediately stopped for patients who experience signs and symptoms of eosinophilic pneumonia, and they should receive appropriate treatment. Corticosteroids are often necessary for recovery. Eosinophilic pneumonia may reoccur with re-exposure to daptomycin.<xref ref-type="bibr" rid="article-32876.r34">[34]</xref><xref ref-type="bibr" rid="article-32876.r35">[35]</xref>&#x000a0;Rare cases of peripheral neuropathy have been observed in patients receiving daptomycin. Therefore, monitoring for new-onset or worsening neuropathy is recommended. Prolonged use of daptomycin can&#x000a0;predispose patients to a superinfection such as&#x000a0;<italic toggle="yes">Clostridioides</italic><italic toggle="yes">&#x000a0;difficile</italic>-associated diarrhea (CDAD) and pseudomembranous colitis.<xref ref-type="bibr" rid="article-32876.r36">[36]</xref><xref ref-type="bibr" rid="article-32876.r37">[37]</xref>&#x000a0;The incidence of CDAD&#x000a0;is greater than&#x000a0;2 months after treatment with daptomycin.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Other medications taken with daptomycin may increase the risk of adverse effects and drug toxicity. Therefore, dosing adjustments, additional monitoring, and alternative treatment should be considered when combining daptomycin with certain medications. Caution is advised when administering daptomycin with HMG-CoA reductase inhibitors (statins), as this can potentially increase the risk of skeletal muscle toxicity.&#x000a0;Statin therapy should&#x000a0;be temporarily discontinued while patients receive treatment with daptomycin. If concomitant administration&#x000a0;is&#x000a0;unavoidable, the patient's CPK levels should be&#x000a0;obtained weekly.<xref ref-type="bibr" rid="article-32876.r33">[33]</xref>&#x000a0;Daptomycin is compatible with 0.9% sodium chloride injection for reconstitution and dilution.&#x000a0;Daptomycin is incompatible with dextrose-containing diluents and should not be used with elastomeric infusion pumps due to the leaching of the impurity 2-mercaptobenzothiazole into the solution. Additives and other medications should not be mixed with or infused simultaneously through the same intravenous line. If the same line is used for sequential infusions, it should be flushed with a compatible intravenous solution before and after daptomycin administration.</p>
      </sec>
      <sec id="article-32876.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Daptomycin is contraindicated&#x000a0;for patients with a known hypersensitivity reaction to the drug or any component within the formulation. Although daptomycin does not have other contraindications to its use, there are significant clinical considerations to remember when caring for patients.</p>
        <p>Pulmonary surfactant inactivates daptomycin. Therefore, it should not be used to treat patients with pneumonia. Daptomycin is not recommended&#x000a0;for pediatric patients younger than&#x000a0;12 months due to&#x000a0;its&#x000a0;adverse effects on the muscular, neuromuscular, or nervous systems.<xref ref-type="bibr" rid="article-32876.r29">[29]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>According to product labeling, daptomycin is not approved for left-sided infective endocarditis caused by&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>.</p>
        <p>
<bold>Bacterial Resistance and&#x000a0;Antimicrobial Stewardship</bold>
</p>
        <p>Like other antibiotics, prolonged or inappropriate treatment with daptomycin can lead to bacterial resistance. Therefore, providers must know about increased antibiotic resistance patterns. In addition, patients should be counseled on the importance of medication adherence to prevent developing multidrug-resistant infections. Prescribing daptomycin without a confirmed or highly suspected bacterial infection or for prophylactic purposes is unlikely to offer therapeutic benefit and may contribute to the emergence of drug-resistant bacteria. Adhering to antimicrobial stewardship principles by ensuring the appropriate use of daptomycin and monitoring for resistance patterns is essential to optimize patient outcomes and minimize resistance development.<xref ref-type="bibr" rid="article-32876.r38">[38]</xref></p>
      </sec>
      <sec id="article-32876.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Patients receiving daptomycin therapy should be monitored to ensure the safe administration&#x000a0;of the medication. Baseline renal function tests are recommended to assess renal impairment and the necessity of dosage adjustments. Additionally, clinicians are recommended to obtain weekly baseline&#x000a0;CPK levels in patients requiring treatment for more than&#x000a0;1 week. More frequent CPK monitoring is necessary for patients with current or prior statin therapy, an unexplained elevation in CPK, or renal impairment.<xref ref-type="bibr" rid="article-32876.r33">[33]</xref><xref ref-type="bibr" rid="article-32876.r39">[39]</xref>&#x000a0;Patients should also receive&#x000a0;monitoring for muscle pain or weakness, new-onset or worsening peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia.<xref ref-type="bibr" rid="article-32876.r34">[34]</xref><xref ref-type="bibr" rid="article-32876.r40">[40]</xref>&#x000a0;Furthermore, patients who develop diarrhea should be tested for <italic toggle="yes">C difficile</italic> infection.</p>
      </sec>
      <sec id="article-32876.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Renal impairment affects daptomycin pharmacokinetics, with mild impairment causing a moderate reduction in clearance. Moderate/severe impairment leads to a decrease in clearance and an increase in the area under the concentration-time curve (AUC). Consequently, overdosing in these populations can lead to significantly elevated systemic drug levels, increasing the risk of adverse effects and toxicity. Patients who overdose on daptomycin may experience myalgia and rhabdomyolysis and have elevated creatine phosphokinase and potassium levels.<xref ref-type="bibr" rid="article-32876.r41">[41]</xref><xref ref-type="bibr" rid="article-32876.r42">[42]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Supportive care is recommended with the maintenance of glomerular filtration in case of overdose suspected or confirmed with daptomycin.</p>
        <list list-type="bullet">
          <list-item>
            <p>Approximately 15% of daptomycin is cleared slowly from the body by hemodialysis (low-flux membrane) over 4 hours. High-flux dialysis membrane hemodialysis may increase the percentage of dose removal.<xref ref-type="bibr" rid="article-32876.r43">[43]</xref></p>
          </list-item>
          <list-item>
            <p>Approximately 11% of daptomycin is cleared by peritoneal dialysis&#x000a0;over 48 hours.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-32876.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare professionals, such as intensivists, infectious disease specialists, internists, and nurse practitioners who prescribe daptomycin, should monitor the patient to ensure safe medication administration. Baseline renal function tests are recommended to assess renal impairment and&#x000a0;the necessity&#x000a0;of dosage adjustments. Additionally, clinicians are advised to obtain&#x000a0;weekly CPK levels in patients requiring treatment for more than&#x000a0;1 week. More frequent monitoring of CPK is necessary for patients with current or prior statin therapy, an unexplained elevation in CPK, or renal impairment. A board-certified infectious disease pharmacist can provide antibiogram data, verify dosing, and work with the nursing staff regarding administration. Nurses can also monitor for adverse events and administer the drug, alerting the attending promptly regarding any concerns.&#x000a0;Patients should also be monitored by nursing staff and clinicians for muscle pain or weakness, new-onset or worsening peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia.</p>
        <p>Furthermore, prescribers should order testing for&#x000a0;<italic toggle="yes">C difficile</italic>&#x000a0;infection when patients develop diarrhea. A prospective quasi-experimental study showed that a pharmacist-led antibiotic stewardship program significantly reduced antimicrobial use and costs, including daptomycin, especially in the absence of an infectious diseases physician consult service. This highlights pharmacists' crucial role in optimizing antimicrobial use and improving practices where ID support is unavailable.<xref ref-type="bibr" rid="article-32876.r44">[44]</xref>&#x000a0;An interprofessional team approach and communication among clinicians, infectious disease specialists, pharmacists, and specialty-trained nurses are crucial to decreasing potential adverse effects, improving disease course and quality of life, and improving patient outcomes&#x000a0;related&#x000a0;to daptomycin therapy.</p>
      </sec>
      <sec id="article-32876.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=32876&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=32876">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/32876/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=32876">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-32876.s11">
        <title>References</title>
        <ref id="article-32876.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tascini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sbrana</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sozio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dal Pino</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bertolino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ripoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pallotto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Emdin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sampietro</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Statins during daptomycin therapy: to give or not to give?</article-title>
            <source>Minerva Anestesiol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>689</fpage>
            <page-range>689-690</page-range>
            <pub-id pub-id-type="pmid">30621379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bricca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goutelle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roux</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gagnieu</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Valour</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Triffault-Fillit</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chidiac</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>T</given-names>
              </name>
              <collab>Lyon Bone and Joint Infection Study Group</collab>
            </person-group>
            <article-title>Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>1012</fpage>
            <page-range>1012-1020</page-range>
            <pub-id pub-id-type="pmid">30629193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dexter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cameron</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Monk</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Baines</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Spelman</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kostoulias</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nethercott</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Peleg</surname>
                <given-names>AY</given-names>
              </name>
            </person-group>
            <article-title>Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>63</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">30617095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Piva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Paolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Galeotti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ceccherini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cordoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Signorini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Togni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>De Nicol&#x000f2;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rasulo</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Fagoni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Latronico</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>D'Avolio</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis.</article-title>
            <source>Neurocrit Care</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-124</page-range>
            <pub-id pub-id-type="pmid">30607829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montravers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Norrby-Teglund</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munoz</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Treating necrotizing skin and soft-tissue infections.</article-title>
            <source>Intensive Care Med</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>8</issue>
            <fpage>1342</fpage>
            <page-range>1342-1345</page-range>
            <pub-id pub-id-type="pmid">38753269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boulekbache</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kavafian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferry</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bourguignon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Goutelle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lega</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Garreau</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2024</year>
            <month>Apr</month>
            <day>02</day>
            <volume>79</volume>
            <issue>4</issue>
            <fpage>712</fpage>
            <page-range>712-721</page-range>
            <pub-id pub-id-type="pmid">38323372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donnelly</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gash</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Connell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dinesh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Getting to the heart of the matter-are two agents really better than one for the treatment of staphylococcal infective endocarditis?</article-title>
            <source>Int J Infect Dis</source>
            <year>2024</year>
            <month>May</month>
            <volume>142</volume>
            <fpage>106975</fpage>
            <pub-id pub-id-type="pmid">38395218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geriak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rizvi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kullar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>LaPlante</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vasina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ouellette</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zervos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nizet</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sakoulas</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>May</month>
            <volume>63</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">30858203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grillon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Argemi</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gaudias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ronde-Ousteau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boeri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jenny</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Hansmann</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jehl</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Bone penetration of daptomycin in diabetic patients with bacterial foot infections.</article-title>
            <source>Int J Infect Dis</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>85</volume>
            <fpage>127</fpage>
            <page-range>127-131</page-range>
            <pub-id pub-id-type="pmid">31096056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x0015e;ahin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalgic</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Intravenous and Intraventricular Daptomycin Plus Intravenous Linezolid Treatment of an Infant with Vancomycin-Resistant Enterococci-Induced Ventriculoperitoneal Shunt Infection.</article-title>
            <source>World Neurosurg</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>124</volume>
            <fpage>328</fpage>
            <page-range>328-330</page-range>
            <pub-id pub-id-type="pmid">30685371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Daum</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fridkin</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Gorwitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Karchmer</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>J Rybak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Talan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>HF</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.</article-title>
            <source>Clin Infect Dis</source>
            <year>2011</year>
            <month>Feb</month>
            <day>01</day>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-92</page-range>
            <pub-id pub-id-type="pmid">21217178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ceccarelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bellelli</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marincola Cattaneo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gregori</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Palmarini</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marotta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Landi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cuzzolino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stefanini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aureli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mastroianni</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Venditti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>d'Ettorre</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sabetta</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Daptomycin-Containing Regimen for Treatment of Staphylococcal or Enterococcal Vertebral Osteomyelitis: A Prospective Clinical Experience.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2020</year>
            <month>Dec</month>
            <day>10</day>
            <volume>9</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">33321967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kharbat</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Purcell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>MacKay</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Methicillin-Resistant Staphylococcus aureus Spinal Epidural Abscess: Local and Systemic Case Management.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>e22831</fpage>
            <pub-id pub-id-type="pmid">35399478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osmon</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Berbari</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Berendt</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lew</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zimmerli</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hanssen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e25</page-range>
            <pub-id pub-id-type="pmid">23223583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cairns</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Udy</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Peel</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Abbott</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Dooley</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Peleg</surname>
                <given-names>AY</given-names>
              </name>
            </person-group>
            <article-title>Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2023</year>
            <month>Jun</month>
            <day>21</day>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>e0005922</fpage>
            <pub-id pub-id-type="pmid">37067406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tzalis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ioannou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Billiari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kofteridis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Karakonstantis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin as an option for lock therapy: a systematic literature review.</article-title>
            <source>Future Microbiol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>18</volume>
            <fpage>917</fpage>
            <page-range>917-928</page-range>
            <pub-id pub-id-type="pmid">37622290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tunkel</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hasbun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhimraj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Byers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Scheld</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>van de Beek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Garton</surname>
                <given-names>HJL</given-names>
              </name>
              <name>
                <surname>Zunt</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2017</year>
            <month>Mar</month>
            <day>15</day>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>e34</fpage>
            <page-range>e34-e65</page-range>
            <pub-id pub-id-type="pmid">28203777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidary</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khosravi</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Khoshnood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasiri</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Soleimani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goudarzi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>73</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">29059358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The action mechanism of daptomycin.</article-title>
            <source>Bioorg Med Chem</source>
            <year>2016</year>
            <month>Dec</month>
            <day>15</day>
            <volume>24</volume>
            <issue>24</issue>
            <fpage>6253</fpage>
            <page-range>6253-6268</page-range>
            <pub-id pub-id-type="pmid">27288182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grein</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scherer</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kl&#x000f6;ckner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sahl</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Kubitscheck</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Ca<sup>2+</sup>-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids.</article-title>
            <source>Nat Commun</source>
            <year>2020</year>
            <month>Mar</month>
            <day>19</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>1455</fpage>
            <pub-id pub-id-type="pmid">32193379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faure</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Manuse</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gonin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grangeasse</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jault</surname>
                <given-names>J-M</given-names>
              </name>
              <name>
                <surname>Orelle</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin avoids drug resistance mediated by the BceAB transporter in <italic>Streptococcus pneumoniae</italic>.</article-title>
            <source>Microbiol Spectr</source>
            <year>2024</year>
            <month>Feb</month>
            <day>06</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>e0363823</fpage>
            <pub-id pub-id-type="pmid">38214521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oleson</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.</article-title>
            <source>Chem Biol Interact</source>
            <year>2004</year>
            <month>Nov</month>
            <day>20</day>
            <volume>150</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-47</page-range>
            <pub-id pub-id-type="pmid">15535984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hagiya</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sugawara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hamaguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nishi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomono</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Emergence of daptomycin non-susceptible coagulase-negative Staphylococci in patients with cardiovascular device infections: Two cases report investigated by whole genome analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>97</volume>
            <issue>49</issue>
            <fpage>e13487</fpage>
            <pub-id pub-id-type="pmid">30544442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leong</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Kurup</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Kwa</surname>
                <given-names>ALH</given-names>
              </name>
              <name>
                <surname>Liau</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics.</article-title>
            <source>Infect Drug Resist</source>
            <year>2018</year>
            <volume>11</volume>
            <fpage>1959</fpage>
            <page-range>1959-1974</page-range>
            <pub-id pub-id-type="pmid">30464538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sipahi</surname>
                <given-names>OR</given-names>
              </name>
              <name>
                <surname>Kahraman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Erdem</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Yetkin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Demirdal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tunccan</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Karasahin</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oruc</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cag</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kurtaran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ulug</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kutlu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Avci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oztoprak</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Arda</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pullukcu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tasbakan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamazhan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kandemir</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dizbay</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sipahi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ulusoy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study.</article-title>
            <source>Infection</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-266</page-range>
            <pub-id pub-id-type="pmid">30498901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frankenfeld</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Melendez</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mendez-Vigo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lamp</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Bertolami</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin: a comparison of two intravenous formulations.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2018</year>
            <volume>12</volume>
            <fpage>1953</fpage>
            <page-range>1953-1958</page-range>
            <pub-id pub-id-type="pmid">29988771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fenton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Curran</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin.</article-title>
            <source>Drugs</source>
            <year>2004</year>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>445</fpage>
            <page-range>445-55; discussion 457-8</page-range>
            <pub-id pub-id-type="pmid">14969579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Daptomycin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>4</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30000665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wasko</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Risk of Daptomycin-associated Myopathy With Concomitant Statin Use.</article-title>
            <source>Clin Infect Dis</source>
            <year>2019</year>
            <month>Jul</month>
            <day>18</day>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>558</fpage>
            <page-range>558-559</page-range>
            <pub-id pub-id-type="pmid">30596967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woods</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Copley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kronman</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Arrieta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Carrillo-Marquez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Eppes</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Stadler</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Mazur</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Creech</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Zaoutis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2021</year>
            <month>Sep</month>
            <day>23</day>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>801</fpage>
            <page-range>801-844</page-range>
            <pub-id pub-id-type="pmid">34350458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Boucher</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Abrutyn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karchmer</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Rupp</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Tally</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Vigliani</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Link</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>DeMeyer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Filler</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Zervos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parsonnet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gareca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rehm</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Brodt</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Tice</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
              <collab>S. aureus Endocarditis and Bacteremia Study Group</collab>
            </person-group>
            <article-title>Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Aug</month>
            <day>17</day>
            <volume>355</volume>
            <issue>7</issue>
            <fpage>653</fpage>
            <page-range>653-65</page-range>
            <pub-id pub-id-type="pmid">16914701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Finkelberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spooner</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2008</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>719</fpage>
            <page-range>719-21</page-range>
            <pub-id pub-id-type="pmid">18381844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dare</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Tewell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Van Driest</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Farber-Eger</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Oct</month>
            <day>15</day>
            <volume>67</volume>
            <issue>9</issue>
            <fpage>1356</fpage>
            <page-range>1356-1363</page-range>
            <pub-id pub-id-type="pmid">29668884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Sorbello</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Wassel</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Pham</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tonning</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Nambiar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports.</article-title>
            <source>Drug Saf</source>
            <year>2012</year>
            <month>Jun</month>
            <day>01</day>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>447</fpage>
            <page-range>447-57</page-range>
            <pub-id pub-id-type="pmid">22612850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gidari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pallotto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Francisci</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series.</article-title>
            <source>Infection</source>
            <year>2024</year>
            <month>Jul</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">39028390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zbylicki</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Petsche</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>M&#x000fc;h</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Dobrila</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Daum</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Pannullo</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ellermeier</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Identification of <italic>Clostridioides difficile</italic> mutants with increased daptomycin resistance.</article-title>
            <source>J Bacteriol</source>
            <year>2024</year>
            <month>Mar</month>
            <day>21</day>
            <volume>206</volume>
            <issue>3</issue>
            <fpage>e0036823</fpage>
            <pub-id pub-id-type="pmid">38376203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awadelkarim</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Idris</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Abdelhai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yeddi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alhusain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dayco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salih</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin-Associated Diarrhea: A Case Report and Review of the Literature.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>e26135</fpage>
            <pub-id pub-id-type="pmid">35747108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kinnear</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Newton</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Read</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Impact of an Antimicrobial Stewardship Intervention on Within- and Between-Patient Daptomycin Resistance Evolution in Vancomycin-Resistant Enterococcus faecium.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30718245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nehring</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Housman</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Possible Hepatotoxicity Associated With Daptomycin: A Case Report and Literature Review.</article-title>
            <source>J Pharm Pract</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-6</page-range>
            <pub-id pub-id-type="pmid">26763341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Villaverde Pi&#x000f1;eiro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rabu&#x000f1;al Rey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Sabina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monte Secades</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a Pais</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Paralysis of the external popliteal sciatic nerve associated with daptomycin administration.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>578</fpage>
            <page-range>578-580</page-range>
            <pub-id pub-id-type="pmid">29383748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sauermann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rothenburger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graninger</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Joukhadar</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin: a review 4 years after first approval.</article-title>
            <source>Pharmacology</source>
            <year>2008</year>
            <volume>81</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-91</page-range>
            <pub-id pub-id-type="pmid">17940348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Errabelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lathiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin-induced hyperkalemia: A case report and brief description of mechanism.</article-title>
            <source>Clin Case Rep</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>e8188</fpage>
            <pub-id pub-id-type="pmid">37965183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haselden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leach</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bohm</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.</article-title>
            <source>Ann Pharmacother</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1342</fpage>
            <page-range>1342-7</page-range>
            <pub-id pub-id-type="pmid">24259698</pub-id>
          </element-citation>
        </ref>
        <ref id="article-32876.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cantudo-Cuenca</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Jim&#x000e9;nez-Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-de la Plata</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacist-led antimicrobial stewardship programme in a small hospital without infectious diseases physicians.</article-title>
            <source>Sci Rep</source>
            <year>2022</year>
            <month>Jun</month>
            <day>09</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>9501</fpage>
            <pub-id pub-id-type="pmid">35680946</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
